How Many Doses of Hepatitis A Vaccine Do You Need?

Most people need two doses of the inactivated hepatitis A vaccine, spaced six to twelve months apart. The first dose triggers protective antibodies in the vast majority of recipients within two weeks, but the second dose is what converts that short-term shield into protection estimated to last decades. The schedule is straightforward, though the details shift for certain groups, and a growing body of evidence from countries using a single-dose strategy has complicated the picture in interesting ways.

What One Dose Does for You

A single shot of inactivated hepatitis A vaccine works faster than many people expect. Clinical trials measuring early antibody responses found that most vaccinated people develop detectable antibodies within two weeks, some as early as twelve days after the injection.¹ In children and adolescents aged two to eighteen, studies have consistently shown that between 97% and 100% have protective antibody levels one month after the first dose.² That rapid response is a big part of why the vaccine can be given right before a trip to a high-risk area and still be useful.

Adults also respond well, though the numbers are slightly less uniform. One study of a single adult-strength dose found a seroconversion rate of about 88% at day fourteen, climbing to roughly 95% by month twelve even before a booster was given.³ So if you’ve had one dose, you’re very likely protected in the short run. The issue is what happens over the following years without that second shot.

Why the Second Dose Matters

The second dose is not really a “booster” in the sense that it rescues a failing immune response. Instead, it dramatically amplifies the antibody levels and locks in immune memory, pushing the likely duration of protection far beyond what a single dose can guarantee. After a standard two-dose course, antibody persistence has been tracked in long-term follow-up studies for twenty years, with more than 97% of vaccinated subjects still seropositive at that point. Mathematical modeling applied to those data projects that at least 95% of recipients will remain protected at year thirty, and 90% or more at year forty.⁴

A broad review of the evidence estimated that two doses of inactivated vaccine provide protection for roughly thirty to forty years in healthy children, adolescents, and young adults, and possibly for life, with no need for a later booster.⁵ A systematic review looking across both inactivated and live attenuated vaccines placed the confirmed protection window at up to fifteen years using conservative thresholds, though the data clearly suggest longer.⁶ No country currently recommends a routine third dose or later booster for people with healthy immune systems who completed the two-dose series.

In a systematic review comparing single-dose and two-dose universal vaccination programs, vaccine effectiveness exceeded 95% over three to five years for two-dose programs. After one dose, effectiveness was actually above 98% over periods up to about seven and a half years in controlled studies, but the persistence of antibodies told a different story: at least 90% of two-dose recipients maintained antibodies for up to fifteen years, while only about 74% of single-dose recipients did so at the ten-year mark.⁷ Effectiveness and antibody persistence are not the same thing, but that gap in long-term antibody retention is the core reason two doses remain the standard recommendation in most countries.

What If You’re Late on the Second Dose

Life gets in the way. People forget, schedules slip, and it is common to show up for a second hepatitis A shot well past the recommended six-to-twelve-month window. The good news is that this vaccine is exceptionally forgiving on timing. You do not need to restart the series. A delayed second dose still produces a strong immune memory response.

One study gave a booster to participants an average of twenty-seven months after the first dose and found robust antibody levels afterward, comparable to those seen in people vaccinated on schedule.⁸ More striking evidence comes from a study that delayed the booster for up to about eleven years. Even at that extreme interval, the booster triggered a full protective immune memory response, including in travelers over age fifty.⁹ The immune system essentially remembers the first dose and mounts a rapid, vigorous response when it encounters the antigen again, regardless of how much time has passed.

The practical takeaway: if you got one dose years ago and never went back for the second, just go get it now. There is no penalty for the delay, and no reason to start over.

Travel and Last-Minute Vaccination

Hepatitis A is one of the most common vaccine-preventable infections in travelers to regions with poor sanitation. Because the first dose works quickly, the vaccine is useful even for last-minute travelers. Most people develop protective antibodies within about two weeks of the shot, which covers the typical gap between booking a trip and departing.¹ If you are leaving sooner than that, the older approach was to add a dose of immune globulin for immediate passive protection, though current U.S. guidelines from 2020 have simplified the recommendation for most healthy adults under forty to vaccine alone.

Travelers should still plan for the second dose after returning. Even though one dose covers a single trip, the whole point of completing the series is that you won’t need to think about hepatitis A again for decades. People who travel frequently to endemic areas get the most value from finishing the two-dose course early.

Older Adults May Respond Differently

Age matters for the first dose more than for the second. In one prospective study, seroprotection after a single dose dropped to about 65% in people over fifty, compared with 100% in younger adults. However, after the booster dose, protection climbed back to 97% in the older group.¹⁰ Antibody levels were also about 1.7-fold lower in the older group at each time point, though the proportional increase after the booster was similar across ages.

This pattern has been confirmed in reviews of the broader literature on hepatitis A vaccines in older adults.¹¹ The message for anyone over fifty who has never been vaccinated is simple: do not assume that one dose will be enough to cover you during an upcoming trip. The second dose matters even more for this group, and getting vaccinated well in advance of travel gives your immune system time to build a full response.

Liver Disease and Immunosuppression

People with chronic liver disease are the ones who most need protection against hepatitis A, since the virus can cause severe complications on top of existing liver damage. Ironically, they are also the ones who respond less well to the vaccine. In patients with chronic hepatitis C or other chronic liver conditions, seroconversion after a single dose ranged from about 74% to 83%, compared with 93% in healthy controls. After the full two-dose course, though, more than 94% of all groups were seropositive.¹²

The situation worsens with more advanced disease. In people with decompensated cirrhosis, only about 37% developed antibodies after a single dose, compared with roughly 71% of those with compensated liver disease. Even after the booster, the gap persisted: about 66% seroconversion in decompensated patients versus 98% in compensated ones. Disease severity, as measured by clinical scoring of liver function, was the strongest predictor of poor vaccine response.¹³ Liver transplant recipients fared worst of all: in one small study, none of the transplant patients responded to the vaccine, compared with half of patients awaiting transplant.¹⁴

The lesson here is that vaccination should happen as early as possible in the course of chronic liver disease, before the liver deteriorates to the point where the immune system can no longer mount an adequate response. Waiting until someone is on a transplant list is too late for many patients.

For people on immunosuppressive medications, the picture depends on the type and intensity of treatment. A systematic review found impaired responses overall, with the weakest responses after just one dose and in organ transplant recipients.¹⁵ A more recent cohort study added nuance: people living with HIV who had suppressed viral loads, and patients on a single immunosuppressive drug, responded about as well as healthy controls after the complete vaccination schedule. But those on combination immunosuppressive therapy, or anyone who didn’t finish the full course, were at risk of failing to respond at all. For these groups, checking antibody levels after vaccination is recommended.¹⁶ The bottom line for anyone who is immunocompromised: two doses are the minimum, and blood testing afterward is a good idea to make sure the vaccine actually worked.

Countries Using a Single-Dose Strategy

While most high-income countries recommend two doses, several middle-income countries have opted for a single-dose universal vaccination program, and the results have drawn serious attention. Argentina introduced a single-dose hepatitis A vaccination for all one-year-olds in 2005. Within a few years, hepatitis A infection rates plummeted by about 88%, and neither fulminant hepatic failure nor liver transplantation due to hepatitis A had been observed since early 2007.¹⁷ Follow-up data showed that protective antibody levels and low disease burden persisted for at least eight to eleven years after the single-dose intervention.¹⁸

These outcomes reflect a combination of direct vaccine protection and herd immunity. When enough children are vaccinated, the virus has fewer hosts to circulate through, which protects even unvaccinated people. Modeling of U.S. data has shown that herd immunity can more than double the benefits of a vaccination program in its early years.¹⁹ Separate modeling estimated that between 1995 and 2001, immunization averted roughly 98,000 hepatitis A cases in the United States when accounting for herd effects, and that vaccination had prevented over half of cases among children aged two to eighteen even with average coverage of only about 10%.²⁰

A single-dose strategy doesn’t mean one dose gives the same individual protection as two. What it means is that, at a population level, one dose per child can be enough to break transmission when coverage is high, especially in countries where the cost of a second dose creates a barrier. Cost-effectiveness analyses from Indonesia found that a single-dose program was cost-effective compared with no vaccination, while moving from one dose to two doses per child was far more expensive relative to the additional benefit gained.²¹ For a country weighing limited health-care dollars, vaccinating more children with one dose each may prevent more disease than vaccinating fewer children with two.

Combination Vaccines for Hepatitis A and B

If you need protection against both hepatitis A and hepatitis B, a combination vaccine exists that covers both. The standard schedule for the combined vaccine is three doses at zero, one, and six months. There’s also an accelerated schedule studied for situations like urgent travel, with three doses given at day zero, day seven, and day twenty-one, followed by a booster at twelve months.²²

In adolescents, a comparison of two- and three-dose regimens of the combined vaccine showed that both produced 100% anti-hepatitis-A seropositivity at the ten-year mark. The two-dose schedule used the higher-strength adult formulation given at zero and six months, while the three-dose schedule used the pediatric formulation at zero, one, and six months. Both were equivalent for long-term hepatitis A antibody persistence.²³ A review of the long-term data concluded that once a full primary course of either the monovalent or combination vaccine is completed, there is no evidence supporting the need for a later hepatitis A or B booster in people with normal immune function.²⁴

Live Attenuated Vaccines

Most of the world uses inactivated hepatitis A vaccines, which are the two-dose products discussed throughout this article. But live attenuated versions, given as a single dose, are used in several countries, most prominently China and parts of South Asia. These work differently: rather than presenting a killed virus that the immune system must learn from passively, they use a weakened live virus that replicates briefly and triggers a broader immune response.

Follow-up data on the live attenuated vaccine have been encouraging. In a seventeen-year follow-up study after a single dose, researchers found that both memory B cells and T cells specific to the hepatitis A virus were still present and responded rapidly when re-exposed to the virus.²⁵ In a study of Indian children, about 98% of those still available for follow-up had protective antibody levels years after a single dose.²⁶ A cost-effectiveness analysis from China found that a single dose of the live attenuated vaccine, preceded by serological screening in adults, was the most cost-saving strategy among all options evaluated.²⁷

If you’re in the United States, Europe, or most other Western countries, the live attenuated vaccine is not licensed or available. Your schedule will be two doses of the inactivated product. But awareness of the live vaccine matters if you encounter vaccination records from countries that use it: a single dose on someone’s record from China, for example, may represent a complete course rather than a half-finished one.

Safety and Side Effects

Hepatitis A vaccines have an excellent safety profile across both formulations and all age groups. The most common side effect is temporary soreness at the injection site. Serious adverse events are rare, and large-scale surveillance data have confirmed the vaccine’s safety over decades of use.²⁸ An interesting wrinkle: mild reactions are actually slightly more common after the first dose than after the second, so if you tolerated the first shot well, the second is unlikely to surprise you.²⁹

Do You Need a Blood Test Before Getting Vaccinated

Some people, especially those born in countries where hepatitis A is common, may already be immune from a childhood infection they never noticed. The question of whether to test for existing immunity before vaccinating has been studied mainly from a cost perspective. The general finding is that pre-vaccination screening is not cost-effective for most people. It only starts to make financial sense when the expected prevalence of existing immunity in the group being tested is above roughly 45%.³⁰ In practice, this means screening may be worthwhile for older adults from endemic countries or certain institutional populations, but for most travelers and younger adults, it is cheaper and simpler to just give the vaccine.³¹

The vaccine is safe to give to someone who is already immune. There is no harm in receiving an unnecessary dose; it just means the immune system encounters an antigen it already recognizes and mounts a quick, uneventful response. So when in doubt, vaccinating without testing is the default approach.